Trinity Biotech Plc (Trinity Biotech) is a biotechnology company that focuses on the development, manufacture, and marketing of diagnostic test kits. The company's products are used in the clinical laboratory and point-of-care segments of the diagnostic market to detect infectious diseases, sexually transmitted diseases, autoimmune disorders, hemoglobin disorders, and in the detection, monitoring, and control of diabetes. Trinity Biotech also provides raw materials to the life sciences industry.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Trinity Biotech’s R&D activities focuses on the development of infectious diseases diagnostics and technological development. The company outsources certain R&D activities to third parties as required. The company also engages in third-party consultants and contractors for the Premier instrument’s development project. It focuses on the product development in hemoglobin, infectious diseases, and CGM. The company has made progress in the development of the Premier Hb9210 instrument for hemoglobin A1c testing and the Premier Resolution instrument for hemoglobin variant testing. Additionally, Trinity Biotech is developing a combination HIV/Syphilis point-of-care rapid test and is further developing the biosensor and CGM assets acquired from Waveform. Trinity Biotech operates manufacturing facilities at Kansas City, Missouri; Williamsville, Amherst and Jamestown, New York; Extrema, Brazil and in Bray, Ireland. The company also owns an additional facility in Burlington, Canada that carries out few research and development activities and primarily serves as a distribution center. In FY2024, the company spent US$4.5 million on its R&D activities, which as a percentage of revenue stood at 7.3%, and grew 3.7% YoY.